~~<i id='CEBA131A68'><strike id='CEBA131A68'><tt id='CEBA131A68'><pre id='CEBA131A68'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：fashion 2025-09-27 11:20:59 Page View：2544

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Pregnant women don't need prenatal multivitamins, study concludes
Next article： Alkermes shareholders re

explore

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Why Talkspace is targeting Medicare, a tricky market

AdobeOverthelastfewyears,virtualmentalhealthcompanyTalkspacehasbeenonarelentlessquesttoconquertheins

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

AdobeSomeofthecountry’sbiggesthealthinsurerssaidTuesdaythatuptoone-quarteroftheirclaimsarerunthrough

WSS

explore

explore

focus

explore

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims